How to Get Addyi in West Virginia: Prescription, Telehealth, and Pharmacy Guide

What Is Flibanserin (Addyi) and Who Qualifies in West Virginia

Flibanserin 100 mg (brand: Addyi) is the only FDA-approved non-hormonal treatment for generalized acquired HSDD in premenopausal women. Qualification requires persistent low sexual desire that causes marked distress, with no adequate explanation from a co-existing medical condition, relationship problem, or drug effect [1].

The FDA approved flibanserin on August 18, 2015, under a Risk Evaluation and Mitigation Strategy (REMS) that restricts dispensing to REMS-certified prescribers and pharmacies [2]. West Virginia follows federal prescribing law on this point, meaning no additional state-level schedule restriction applies beyond the REMS. Flibanserin is not a controlled substance under the DEA Controlled Substances Act, which simplifies interstate telehealth prescribing relative to, say, testosterone or benzodiazepines [2].

Diagnosis rests on clinical interview rather than laboratory values. The Decreased Sexual Desire Screener (DSDS) takes roughly five minutes and is validated for primary-care settings [3]. A score consistent with generalized acquired HSDD, combined with clinician-assessed distress, is sufficient for a prescription. Hormonal workup (FSH, estradiol, testosterone, TSH) is optional but often ordered to exclude secondary causes of low desire, particularly in women aged 35 and older approaching perimenopause [4].

The BEGONIA trial (N=949, 24-week, double-blind, randomized) found flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo, with a mean difference of 0.5 SSEs per 28 days (P<0.001) [5]. Desire scores on the Female Sexual Function Index (FSFI) desire subscale also improved significantly. Dizziness, somnolence, nausea, and fatigue were the most common adverse effects, each occurring in 8 to 11 percent of active-treatment participants [5].

The FDA REMS Program: What It Means for WV Patients

Every prescriber who writes flibanserin must enroll in the ADDYI REMS Program before transmitting a prescription. This is a federal requirement that applies uniformly in all 50 states, including West Virginia [2].

Enrollment takes approximately 15 to 30 minutes online at the ADDYI REMS website. The prescriber completes a one-time training module covering the boxed warning (severe hypotension and syncope when combined with alcohol or CYP3A4 inhibitors), counsels the patient on complete alcohol avoidance, and documents that counseling in the patient chart [2]. The patient then signs a Patient-Prescriber Agreement Form (PPAF) acknowledging the alcohol restriction. Telehealth visits satisfy the counseling requirement; the PPAF may be signed electronically under West Virginia's Uniform Electronic Transactions Act (W. Va. Code §39A-1-1 et seq.).

Dispensing pharmacies must also hold REMS certification. The national specialty pharmacy Sprout-authorized network handles most branded Addyi fills. Many independent and chain pharmacies in West Virginia can obtain REMS certification, though availability varies by county. Patients in rural WV counties, where specialty pharmacy access is limited, may find mail-order REMS pharmacies more practical [6].

The boxed warning specifies that alcohol must be avoided for at least two hours before taking flibanserin and until the next morning. Co-administration with moderate or strong CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit juice in large quantities) is contraindicated because plasma flibanserin concentrations rise four-fold to nine-fold, dramatically amplifying hypotension risk [2].

Telehealth Prescribing for Addyi in West Virginia

West Virginia permits synchronous audio-video telehealth prescribing by licensed providers, and the state Medical Practice Act does not require an in-person prior visit for most non-controlled medications [7]. Because flibanserin is not a controlled substance, a prescriber who holds an active WV license (or who operates under the interstate compact for a covered specialty) can write the prescription after a compliant telehealth evaluation.

The visit itself typically covers: symptom history using the DSDS or Female Sexual Distress Scale-Revised (FSDS-R), medication reconciliation to screen for CYP3A4 inhibitors and CNS depressants, alcohol-use history, blood pressure baseline, and REMS counseling [3]. Most telehealth platforms that operate in WV complete this intake asynchronously before the live video call, reducing the visit to 15 to 25 minutes [6].

HealthRX Four-Step Telehealth Pathway for WV Patients

1. Complete an online intake form that includes the DSDS, FSDS-R, and a full medication list.
2. Attend a synchronous video visit with a REMS-certified prescriber licensed in West Virginia.
3. Sign the Patient-Prescriber Agreement Form electronically and receive the prescription sent to a REMS-certified pharmacy (mail-order or local WV).
4. Receive the medication, typically within 3 to 7 business days from prescription finalization.

West Virginia's Medicaid telehealth parity law (W. Va. Code §33-15-4s) requires commercial insurers to reimburse telehealth visits at parity with in-person rates, though the drug cost itself remains the patient's responsibility given the lack of Medicaid formulary coverage [7].

Labs Required Before Starting Addyi in WV

No laboratory test is mandated by the FDA REMS or the Addyi prescribing label before initiating treatment [2]. Blood pressure measurement (in-office or via a validated home device) is the only physiologic assessment specified in labeling guidance, establishing a baseline before the hypotension risk is introduced.

Clinicians at HealthRX routinely check a targeted panel to rule out secondary causes of low desire. A reasonable approach includes TSH (hypothyroidism is a common reversible cause), free testosterone and SHBG (to evaluate androgen insufficiency, though no FDA-approved threshold defines "low" for women), FSH and estradiol (to detect occult perimenopause), and a fasting lipid panel if cardiovascular risk factors are present [4]. These tests are optional, not obligatory, and a prescriber can lawfully initiate flibanserin without them if the clinical picture is clear.

Liver function tests merit consideration in women who use alcohol regularly, given flibanserin's hepatic metabolism via CYP3A4 and the additive hypotension risk in hepatic impairment [2]. The prescribing label states that flibanserin is contraindicated in patients with hepatic impairment [2].

Women with a history of syncope, orthostatic hypotension, or who take antihypertensive agents need extra scrutiny. A seated-to-standing blood pressure check, or a review of recent ambulatory readings, helps quantify that risk before prescribing [4].

Cost, Insurance, and Prior Authorization in West Virginia

Branded Addyi carries a list price of approximately $800 to $900 per 30-tablet supply. Most commercial insurance plans in West Virginia classify it as a Tier 3 or Tier 4 specialty drug, and prior authorization (PA) is required on the majority of formularies that include it at all [6].

A typical PA submission for a WV commercial insurer includes: the ICD-10 code F52.0 (hypoactive sexual desire dysfunction), documentation of HSDD diagnosis using a validated screener or clinical narrative, confirmation of premenopausal status, notation that hormonal causes have been excluded or addressed, and prescriber attestation of REMS enrollment [6]. Some insurers additionally request failure of at least one psychotherapy or behavioral intervention, though this is not an FDA requirement and can be challenged on appeal.

WV Medicaid does not cover flibanserin as of 2025. Patients on Medicaid should ask about the Sprout Pharmaceuticals patient assistance program, which has historically provided free or low-cost medication to women below 400 percent of the federal poverty line. The company's commercial co-pay card can reduce out-of-pocket costs to as low as $99 per month for commercially insured patients who qualify [6].

Generic flibanserin entered the U.S. market after Sprout's exclusivity period, and several 503A compounding pharmacies now compound flibanserin 100 mg capsules using USP-grade API. In West Virginia, a 503A pharmacy that holds an active WV Board of Pharmacy license may compound and dispense flibanserin for individual patient prescriptions, provided the pharmacy also holds REMS certification [2]. Compounded versions are generally priced at $150 to $350 per month, a meaningful reduction from brand cost [6].

Who Can Prescribe Addyi in West Virginia

Any licensed prescriber in West Virginia who completes REMS enrollment may prescribe flibanserin. This group includes physicians (MD and DO), nurse practitioners (NP) operating under their full-practice-authority status under WV Code §30-7-15a, and physician assistants (PA) practicing under a collaborative agreement [7].

West Virginia granted full practice authority to APRNs in 2016 (SB 317), meaning NPs do not require physician supervision to prescribe non-controlled medications. A telehealth NP licensed in WV, enrolled in ADDYI REMS, can therefore complete the entire prescribing workflow independently [7].

Psychiatrists and gynecologists are most familiar with HSDD in academic settings, but primary care providers, internists, and family medicine practitioners write the majority of flibanserin prescriptions nationally [3]. Specialty referral is not required. If a patient's low desire appears to stem substantially from a comorbid psychiatric condition (major depressive disorder, PTSD, antidepressant-induced sexual dysfunction), involving a mental health provider alongside the prescriber is clinically appropriate, though it does not change the prescribing eligibility rules [4].

The prescriber's WV license must be active and in good standing. Out-of-state telehealth providers who want to serve WV patients must either hold a WV license or qualify under the Interstate Medical Licensure Compact (IMLC), which West Virginia joined in 2017 [7].

Transferring an Existing Addyi Prescription to West Virginia

Patients who move to West Virginia or establish new care with a WV provider while already on flibanserin can transfer their prescription, subject to standard pharmacy-transfer rules. Because flibanserin is non-controlled, WV pharmacy law imposes no additional transfer restrictions beyond those applicable to any Schedule-exempt drug [7].

The receiving WV pharmacy must itself be REMS-certified. If the patient's current mail-order pharmacy already holds REMS certification and ships to WV addresses, no transfer is technically required; the prescription can continue filling through the same channel [2].

The new WV prescriber should document a medication reconciliation note, confirming current alcohol use status, blood pressure, any new CYP3A4 inhibitors in the regimen, and ongoing HSDD symptoms. The PPAF is specific to the prescriber-patient pair, so a new form must be signed with each new prescriber, even if the patient previously signed one with an out-of-state clinician [2].

If the patient's prior insurer covered Addyi and the new WV plan does not, a fresh PA submission under the WV formulary criteria will be needed. Retaining records from the previous insurer's approval (including clinical documentation submitted at that time) accelerates the WV PA process [6].

Managing Addyi: Dosing, Duration, and What to Expect

The approved dose is one 100 mg tablet taken orally at bedtime, every night. Bedtime administration is mandatory rather than optional. Taking the dose at any other time of day dramatically increases the incidence of hypotension, syncope, and accidental injury due to central nervous system depression [2].

Patients and prescribers should set a realistic timeline for response. Clinical trial data show that meaningful improvements in SSEs and desire scores typically appear within 4 to 8 weeks, with maximal effect at 8 to 12 weeks of consistent nightly use [5]. The FDA label recommends discontinuing treatment after 8 weeks if the patient reports no clinically meaningful benefit, because continued exposure in non-responders adds risk without reward [2].

Approximately 13 percent of patients discontinue flibanserin within the first 8 weeks due to adverse effects in controlled trial data, most often somnolence and dizziness [5]. Both effects are substantially worse when alcohol is present, reinforcing the boxed warning's zero-tolerance approach. Patients should also be counseled that drowsiness the morning after the dose (next-day somnolence) can impair driving; they should allow at least 6 hours of sleep before operating a vehicle [2].

Blood pressure should be re-checked at the first follow-up visit, typically 4 weeks after initiation, especially in women who report light-headedness or near-fainting episodes. Any new CYP3A4 inhibitor added to the regimen after flibanserin is started (including azole antifungals prescribed for vaginal candidiasis) should trigger an automatic prescriber alert, since fluconazole single-dose 150 mg raises flibanserin AUC by approximately 7-fold [2].

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on female sexual dysfunction states: "For women with generalized acquired HSDD who have not responded to non-pharmacologic therapy, flibanserin is an approved pharmacologic option, with the understanding that effect sizes are modest and patient selection should account for the alcohol interaction" [8].

Long-term data beyond 24 weeks are limited. The extension phase of BEGONIA and pooled data from three key trials (DAISY, VIOLET, SNOWDROP; combined N=2,997) suggest that SSE improvements are maintained at 52 weeks in women who remain on therapy, though no head-to-head trial against bremelanotide (Vyleesi) exists to guide comparative selection [5].

Flibanserin vs. Bremelanotide: Choosing the Right Agent for WV Patients

Two FDA-approved pharmacologic options exist for HSDD in premenopausal women: flibanserin (daily oral) and bremelanotide 1.75 mg subcutaneous injection (on-demand, up to once per 24 hours) [9]. The choice depends on patient preference, comorbidities, and practical considerations.

Flibanserin suits women who prefer a daily oral tablet and can commit to strict alcohol avoidance. Bremelanotide suits women who prefer on-demand dosing and have no history of cardiovascular disease, given that bremelanotide transiently raises mean arterial blood pressure by approximately 1 to 2 mmHg for about 12 hours post-injection [9]. Neither agent is appropriate in pregnancy.

Bremelanotide (Vyleesi) holds its own FDA prescribing label and REMS-like safety requirements, but it is not subject to the same alcohol restriction as flibanserin [9]. For WV patients who consume alcohol socially and find complete abstinence impractical, bremelanotide may be a more suitable first-line choice.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not endorse one over the other, instead calling for shared decision-making and consideration of individual patient factors including comorbidities and lifestyle [4]. West Virginia prescribers operating through telehealth platforms can prescribe either agent after the appropriate REMS or safety counseling requirements are met.